- Trials with a EudraCT protocol (67)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (26)
67 result(s) found for: Brainstem.
Displaying page 1 of 4.
EudraCT Number: 2018-001466-42 | Sponsor Protocol Number: 17-HPNCL-02 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Fondation Lenval - Hôpitaux Pédiatriques de Nice CHULENVAL | |||||||||||||
Full Title: EFFECTIVENESS OF INTRANASAL DEXMEDETOMIDINE FOR SEDATED AUDITORY BRAINSTEM RESPONSE TESTING | |||||||||||||
Medical condition: Child requiring auditory evaluation in a context of suspicion of deafness, language delay, overall developmental delay, risk factors for hearing loss. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002654-79 | Sponsor Protocol Number: P160954J | Start Date*: 2019-02-13 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: TEMOTRAD 01 : First-line chemotherapy with temozolomide alone for non-enhancing adult brainstem gliomas, with a diffuse subtype and showing clinical and/or radiological infiltrative pattern of pro... | |||||||||||||
Medical condition: adult brainstem gliomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000758-37 | Sponsor Protocol Number: NO18517 | Start Date*: 2016-08-23 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche AG | ||||||||||||||||||
Full Title: A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas | ||||||||||||||||||
Medical condition: High Grade Glioma Brainstem Glioma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001045-12 | Sponsor Protocol Number: NO21125 | Start Date*: 2016-07-20 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche AG | |||||||||||||
Full Title: A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas. | |||||||||||||
Medical condition: Intrinsic Brainstem Glioma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001768-60 | Sponsor Protocol Number: CNS 2007 04 | Start Date*: 2007-10-01 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide with Radiotherapy in Diffuse Pontine Gliomas | |||||||||||||
Medical condition: Diffuse pontine glioma in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003362-84 | Sponsor Protocol Number: FSJD-DIPG-DC | Start Date*: 2016-05-18 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
Full Title: Phase Ib clinical trial on the safety of immunotherapy with autologous dendritic cells primed with lysate allogeneic tumor lines in patients with diffuse intrinsic pontine glioma ( DIPG ) | |||||||||||||
Medical condition: Diffuse intrinsic pontine glioma (DIPG) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002185-23 | Sponsor Protocol Number: DIPG | Start Date*: 2015-07-29 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiotherapy and multiple elective radiotherapy courses with concom... | |||||||||||||
Medical condition: diffuse intrinsic pontine glioma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000095-28 | Sponsor Protocol Number: H3E-MC-JMHW | Start Date*: 2017-03-02 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: A Phase II Study of Pemetrexed in Children with Recurrent Malignancies | ||
Medical condition: Recurrent Malignancies (recurrent solid tumors): Target tumor types were osteosarcoma, Ewing sarcoma/peripheral PNET, rhabdomyosarcoma, neuroblastoma (measurable disease), neuroblastoma (metaiodob... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-016080-11 | Sponsor Protocol Number: DIPGstudyVUmc01 | Start Date*: 2011-02-25 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: A COMPREHENSIVE AND TARGETED THERAPY APPROACH IN PEDIATRIC MALIGNANT PONTINE GLIOMAS | |||||||||||||
Medical condition: Pediatric malignant pontine gliomas | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004125-23 | Sponsor Protocol Number: CCRG19-002 | Start Date*: 2021-05-10 | |||||||||||||||||||||
Sponsor Name:Antwerp University Hospital | |||||||||||||||||||||||
Full Title: Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma | |||||||||||||||||||||||
Medical condition: Childhood high-grade glioma and diffuse intrinsic pontine glioma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016870-33 | Sponsor Protocol Number: CILENT-0902 | Start Date*: 2010-05-20 | |||||||||||
Sponsor Name:Centre Oscar Lambret | |||||||||||||
Full Title: Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study | |||||||||||||
Medical condition: Newly diagnosed diffuse intrinsic pontine glioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000636-40 | Sponsor Protocol Number: PNOC022 | Start Date*: 2022-10-20 | |||||||||||||||||||||
Sponsor Name:Pacific Pediatric Neuro-Oncology Consortium (PNOC) | |||||||||||||||||||||||
Full Title: PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initi... | |||||||||||||||||||||||
Medical condition: Diffuse Midline Gliomas, H3K27M mutant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004321-16 | Sponsor Protocol Number: CCOA566A2417 | Start Date*: 2017-08-31 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: A study of the effects of Coartem, Malarone and artesunate-mefloquine on auditory function in patients 12 years of age or older with acute uncomplicated P. falciparum malaria | ||
Medical condition: This study assessed the effects of artemether-lumefantrine on the auditory nerve pathway as assessed by Auditory Brainstem Response (ABR) and audiometric testing in acute uncomplicated Plasmodium f... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-000962-23 | Sponsor Protocol Number: REDEX | Start Date*: 2014-07-10 |
Sponsor Name:Consorci Parc de Salut Mar | ||
Full Title: Effect of dexmedetomidine on monitoring of motor evoked potentials in patients undergoing supratentorial craniotomy or brainstem surgery | ||
Medical condition: Patients scheduled for supratentorial craniotomy or brainstem surgery with intraoperative monitoring of motor evoked potentials (MEP). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001929-32 | Sponsor Protocol Number: 2014/2126 | Start Date*: 2014-08-25 | |||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||
Full Title: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | |||||||||||||
Medical condition: Diffuse Intrinsic Pontine Glioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) ES (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001965-34 | Sponsor Protocol Number: oral-CORTEM | Start Date*: 2012-11-07 | |||||||||||
Sponsor Name:Servicio de Neurología, HU. Germans Trias i Pujol | |||||||||||||
Full Title: Multicenter, randomized, double-blind clinical trial to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse. | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001481-23 | Sponsor Protocol Number: P160927J | Start Date*: 2017-09-12 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL WITH RILUZOLE IN SPINOCEREBELLAR ATAXIA TYPE 2 | |||||||||||||
Medical condition: SCA2 patients, both gender, at least 18 years of age | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005460-80 | Sponsor Protocol Number: JMV001 | Start Date*: 2006-12-05 |
Sponsor Name:N/A | ||
Full Title: A single center, randomized, open-label, comparative study to assess efficacy and safety of piracetam 4.8g/d administered for 6 months as adjuvant to standard vestibular rehabilitation (VR) therapy... | ||
Medical condition: moderate to severe vertigo of peripheral origin | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022772-31 | Sponsor Protocol Number: 20100812v2 | Start Date*: 2011-02-09 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Psychiatrie und Psychotherapie | |||||||||||||
Full Title: Brain Network Dysfunction as a Model for Schizophrenia: Connectivity Alterations using Ketamine and pharmacological Magnetic Resonance Imaging | |||||||||||||
Medical condition: Quantify changes of resting-state functional connectivity in response to Esketamine in healthy volunteers. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004187-56 | Sponsor Protocol Number: HIT-HGG-2013 | Start Date*: 2017-04-24 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: First-line therapy of newly diagnosed, previously untreated high grade glioma, diffuse pontine glioma, and gliomatosis cerebri in children and adolescents <18 years. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
